PodParley PodParley
PodParley
Reverb Therapeutics Co-Founder & CEO David de Graaf and antibody expert Jonathan Davis discuss the science of bispecifics and multispecifics and what the future holds for these modalities episode artwork

EPISODE · Apr 16, 2026 · 36 MIN

Reverb Therapeutics Co-Founder & CEO David de Graaf and antibody expert Jonathan Davis discuss the science of bispecifics and multispecifics and what the future holds for these modalities

from The Studio at Kendall Square · host BiotechTV

They walk us through the history of bispecifics, which have been talked about since the early 2000's, and the use cases for them today. Plus, a deep dive into the science, which includes discussing your body's reaction to then, affinity & avidity, CMC, and 'bead-on-a-string' approaches that some have used lately. Finally, a discussion of what the future holds.

Episode metadata supplied by the publisher feed · Published Apr 16, 2026

Embed this episode

Ready to play

Reverb Therapeutics Co-Founder & CEO David de Graaf and antibody expert Jonathan Davis discuss the science of bispecifics and multispecifics and what the future holds for these modalities

0:00 36:21

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Studio at Kendall Square?

This episode is 36 minutes long.

When was this The Studio at Kendall Square episode published?

This episode was published on April 16, 2026.

Can I download this The Studio at Kendall Square episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!